FLGT - Fulgent Genetics, Inc.
| Previous Close | 13.64 |
| Open | 13.59 |
| Bid | 13.57 x 1100 |
| Ask | 13.60 x 900 |
| Day's Range | 13.10 - 14.23 |
| 52 Week Range | 3.09 - 16.50 |
| Volume | 316,656 |
| Avg. Volume | 265,796 |
| Market Cap | 254M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.12 |
| Earnings Date | Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.15 |
- Thomson Reuters StreetEvents
Edited Transcript of FLGT earnings conference call or presentation 4-Nov-19 9:30pm GMT
Q3 2019 Fulgent Genetics Inc Earnings Call
- GlobeNewswire
Representatives of Fulgent Genetics to Participate in the Piper Jaffray 31st Annual Healthcare Conference
A live webcast of the question and answer session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times.
- Zacks
Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals
Zacks.com featured highlights include: Brinker International, Sonic Automotive, Fulgent Genetics, Hewlett Packard and Regeneron Pharmaceuticals
- Zacks
Buy These 5 Top-Ranked Stocks With Upgraded Broker Ratings
By following broker rating upgrades, an investor can easily find attractive stocks.
- GlobeNewswire
Fulgent Genetics Announces Pricing of Public Offering of Common Stock
The Company has also granted the underwriters a 30-day option to purchase up to 348,750 additional shares of common stock. The Company currently intends to use the net proceeds from this offering for working capital and general corporate purposes. The shares are being offered by Fulgent Genetics by means of a prospectus supplement to the prospectus forming a part of the Company’s effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2019 and other related documents.
- GlobeNewswire
Fulgent Genetics Announces Proposed Public Offering of Common Stock
In connection with this offering, Fulgent Genetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Fulgent Genetics. The Company currently intends to use the net proceeds from this offering for working capital and general corporate purposes.
- Simply Wall St.
How Much Of Fulgent Genetics, Inc. (NASDAQ:FLGT) Do Insiders Own?
If you want to know who really controls Fulgent Genetics, Inc. (NASDAQ:FLGT), then you'll have to look at the makeup...
- Zacks
Find Strong Buy Stocks with this Filtered Zacks Rank 5 Stock Screener
Find Strong Buy Stocks with this Filtered Zacks Rank 5 Stock Screener
- Zacks
FULGENT GENETIC (FLGT) Is Up 68.12% in One Week: What You Should Know
Does FULGENT GENETIC (FLGT) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Top Ranked Momentum Stocks to Buy for November 11th
Top Ranked Momentum Stocks to Buy for November 11th
- Zacks
Surging Earnings Estimates Signal Upside for FULGENT GENETIC (FLGT) Stock
FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- GlobeNewswire
Fulgent Genetics Reports Third Quarter 2019 Financial Results
Third Quarter 2019 Results: Record billable tests of 20,697, growing 272% year over yearRecord revenue of $10.3 million, growing 84% year over yearGross Margin improves 8.9.
- GlobeNewswire
Fulgent Genetics to Announce Third Quarter 2019 Financial Results on Monday November 4, 2019
Fulgent Genetics, Inc. (FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2019 financial results after the market closes on Monday November 4, 2019. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care.
- Simply Wall St.
Does Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Salary Reflect Performance?
Ming Hsieh has been the CEO of Fulgent Genetics, Inc. (NASDAQ:FLGT) since 2016. This report will, first, examine the...
- Simply Wall St.
Shareholders Are Thrilled That The Fulgent Genetics (NASDAQ:FLGT) Share Price Increased 235%
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
- GlobeNewswire
Fulgent Genetics Launches Picture Genetics, a Consumer-Initiated Genetic Testing Offering
Fulgent Genetics (FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced the launch of Picture Genetics, a new line of at-home genetic testing offerings for the everyday consumer. Picture Genetics will offer three separate consumer-initiated screening tests, which will enable individuals to access Fulgent’s advanced genetic testing and analytics capabilities from the ease and comfort of home at an affordable price point.
- Zacks
Fulgent Genetics, Inc. (FLGT) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Fulgent Genetics, Inc. (FLGT).
- Simply Wall St.
Did Fulgent Genetics, Inc. (NASDAQ:FLGT) Insiders Sell Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- Thomson Reuters StreetEvents
Edited Transcript of FLGT earnings conference call or presentation 5-Aug-19 8:30pm GMT
Q2 2019 Fulgent Genetics Inc Earnings Call
- GlobeNewswire
Fulgent Genetics Reports Second Quarter 2019 Financial Results
Second Quarter 2019 Results: Record billable tests of 16,369, growing 187% year over yearRecord revenue of $8.4 million, growing 56% year over yearGross Margin improves more.
- ACCESSWIRE
Fulgent Genetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Fulgent Genetics, Inc. (NASDAQ: FLGT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 5, 2019 at 4:30 ...
- GlobeNewswire
Fulgent Genetics Names Linda Marsh to Board of Directors
Fulgent Genetics, Inc. (FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to its board of directors, effective August 1. “We’re honored to welcome Ms. Marsh to our Board of Directors,” said Ming Hsieh, Chairman and Chief Executive Officer of Fulgent Genetics. “Her knowledge and expertise in the healthcare industry, government relations and reimbursement will bring invaluable insight to our Board of Directors, and to Fulgent Genetics as a whole.
- GlobeNewswire
Fulgent Genetics Receives Laboratory Permit and Genetic Test Approval from New York State Department of Health
Fulgent Genetics (FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced that the company has received approval from the New York State Department of Health (NYSDOH) to offer next generating sequencing in the state of New York. The NYSDOH has issued to Fulgent Genetics a clinical laboratory permit in the category Genetic Testing - Molecular. Fulgent Genetics leverages a proprietary technology platform to offer one of the most comprehensive genetic testing solutions in the market, providing flexibility and customization on panels for over 18,000 genes.
- Zacks
FULGENT GENETIC (FLGT) Reports Next Week: What Awaits?
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Fulgent Genetics to Announce Second Quarter 2019 Financial Results on Monday August 5, 2019
Fulgent Genetics, Inc. (FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2019 financial results after the market closes on Monday August 5, 2019. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care.
